Defibrio

Defibrio is a pioneering company in the medical technology sector, focused on developing personal Automatic External Defibrillators (AEDs) to combat Sudden Cardiac Arrest (SCA). SCA has a low survival rate of 10% and claims millions of lives annually, with 70% of these deaths occurring at home where immediate access to an AED is often unavailable. Defibrio's innovative AEDs are designed to be personal, connected, and always up-to-date, providing immediate shock delivery and real-time connectivity with emergency dispatchers. The devices utilize AI and machine learning to optimize every step of the rescue process, from initial shock delivery to data transmission for paramedics and hospitals. Defibrio serves a broad market, including individual consumers, healthcare providers, and emergency response teams. The company's business model revolves around the sale of these advanced AED units and subscription services for continuous updates and connectivity features. Revenue is generated through direct sales, subscription fees, and potential partnerships with healthcare institutions. By making AEDs more accessible and efficient, Defibrio aims to significantly increase survival rates for SCA victims.

Keywords: Personal AEDs, Sudden Cardiac Arrest, real-time connectivity, AI optimization, emergency response, healthcare technology, medical devices, survival rates, data transmission, subscription services.